Company: STAA
Filing Date: 2025-12-17
Form Type: DFAN14A
Source: 0001213900-25-122870
Chunk: 2

Company: STAAR SURGICAL CO
Filing Date: 2025-12-17
Form: DFAN14A
Chunk 2
---
 AND ANY OTHER RELEVANT DOCUMENTS THAT THE PARTICIPANTS WILL FILE WITH THE SEC WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION, INCLUDING ABOUT THE MATTERS TO BE VOTED ON AT THE STOCKHOLDER MEETING AND ADDITIONAL INFORMATION RELATING TO THE PARTICIPANTS AND THEIR DIRECT OR INDIRECT INTERESTS, BY SECURITY HOLDINGS OR OTHERWISE. The definitive proxy statement and an accompanying GREEN Proxy Card will be furnished to some
or all of the Company’s stockholders and will be, along with other relevant documents, available at no charge on the SEC’s
website at https://www.sec.gov/.

Information about the Participants and a description
of their direct or indirect interests, by security holdings or otherwise, is contained on an amendment to Schedule 13D filed by the Participants
with the SEC on November 21, 2025 and is available here.

Exhibit 1

<div align='center'>Broadwood Partners Issues Open Letter to STAAR Surgical Board Pledging Cooperation and Support When Vote on Alcon Transaction Fails

Expresses Confidence in STAAR’s Future and the Opportunity for Significant Value Creation

Believes STAAR is Worth at Least $50 Per Share If the Company Is Run in Best Interest of Shareholders</div>

New York – (BUSINESS WIRE) – Broadwood Partners, L.P. and its affiliates (collectively, “Broadwood”) today
issued the following letter to the Board of Directors (the “Board”) of STAAR Surgical Company (“STAAR” or the
“Company”) (NASDAQ: STAA). Broadwood, which owns 30.2% of STAAR’s outstanding common stock, continues to urge its fellow
shareholders to vote “AGAINST” the proposed acquisition of STAAR by Alcon Inc. (“Alcon”) (NYSE:
ALC).

Shareholders can find additional information at www.LetSTAARShine.com.

December 17, 2025

STAAR Surgical Company
25510 Commercentre Dr.
Lake Forest, CA 92630

Dear Members of the Board:

Since the announcement of STAAR’s proposed
sale to Alcon in August, we have been engaged in a spirited debate with you over the Company’s prospects and the merits of the proposed
deal. As you know, we have felt from the start that this transaction materially undervalues STAAR and was the product of a deeply flawed
process undertaken at the wrong time in STAAR’s history.

As we approach the thrice